Novartis Takes On Servier’s Antidepressant
This article was originally published in The Pink Sheet Daily
Novartis is poised to enter the depression market through a licensing agreement with Servier
You may also be interested in...
EMEA’s review committee recommends against authorization of agomelatine, but sides with Gardasil and Champix/Chantix.
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago